144 related articles for article (PubMed ID: 12230858)
21. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
22. Don't feed the trolls.
Nature; 2014 Jun; 510(7503):7. PubMed ID: 24910865
[No Abstract] [Full Text] [Related]
23. Reach-through claims for drug target patents: Rx for pharmaceutical policy.
Bohrer RA
Nat Biotechnol; 2008 Jan; 26(1):55-6. PubMed ID: 18183015
[No Abstract] [Full Text] [Related]
24. AIDS and drug pricing: in search of a policy.
Salbu SR
Wash Univ Law Q; 1993; 71(3):691-734. PubMed ID: 11652750
[No Abstract] [Full Text] [Related]
25. Rights, patents, markets and the global AIDS pandemic.
Gathii JT
Fla J Int Law; 2002; 14(2):261-352. PubMed ID: 16526139
[No Abstract] [Full Text] [Related]
26. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
Ghosh S
Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
[No Abstract] [Full Text] [Related]
27. An ethical dilemma. Patents & profits v. access & affordability.
Blasi AE
J Leg Med; 2012 Jan; 33(1):115-28. PubMed ID: 22439710
[No Abstract] [Full Text] [Related]
28. Access to essential medicines: a Hobbesian social contract approach.
Ashcroft RE
Dev World Bioeth; 2005 May; 5(2):121-41. PubMed ID: 15842722
[TBL] [Abstract][Full Text] [Related]
29. Essential AIDS medications in India.
Thomas J
Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350
[No Abstract] [Full Text] [Related]
30. The policy outlook from the Hill.
Vastag B
Nat Biotechnol; 2007 Jan; 25(1):13-6. PubMed ID: 17211381
[No Abstract] [Full Text] [Related]
31. Patent infringement.
Kempton L
Nat Rev Drug Discov; 2005 Feb; 4(2):97. PubMed ID: 15756754
[No Abstract] [Full Text] [Related]
32. Public-private partnerships in biomedical research: resolving conflicts arising under the Federal Technology Transfer Act of 1986.
Bulleit TN
J Law Health; 1989-1990; 4(1):1-20. PubMed ID: 11652568
[No Abstract] [Full Text] [Related]
33. A new world order for human experiments.
Moreno JD
Account Res; 2003; 10(1):47-56. PubMed ID: 14552300
[No Abstract] [Full Text] [Related]
34. Health-care patents and interests of patients.
Luthra R
Bull World Health Organ; 2006 Nov; 84(11):919. PubMed ID: 17143470
[No Abstract] [Full Text] [Related]
35. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
36. War on terror. A run on antibiotics.
Cowley G
Newsweek; 2001 Oct; 138(17):36-7. PubMed ID: 11682909
[No Abstract] [Full Text] [Related]
37. International patent protection for HIV-related therapies: patent attorney's perspective.
Pavento LC; Greene JL; McDonald JK
Emory Int Law Rev; 2003; 17(2):919-31. PubMed ID: 15199935
[No Abstract] [Full Text] [Related]
38. Should genes be patented? The gene patenting controversy: legal, ethical, and policy foundations of an international agreement.
Looney B
Law Policy Int Bus; 1994; 26(1):231-72. PubMed ID: 11979605
[No Abstract] [Full Text] [Related]
39. Should the patent system for new medicines be abolished?
DiMasi JA; Grabowski HG
Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
[No Abstract] [Full Text] [Related]
40. Patent protection versus public health.
Lancet; 2001 Nov; 358(9293):1563. PubMed ID: 11716874
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
